Chronic Myeloid Leukemia (CML) is a form of cancer that affects the bone marrow and blood. It is characterized by the uncontrolled growth of immature white blood cells in the bone marrow. CML is usually caused by a genetic abnormality known as the Philadelphia chromosome, which results in the production of an abnormal protein called BCR-ABL1.
Phases of CML:
CML has three phases:
- Chronic Phase: This is the initial phase, where the number of immature white blood cells in the bone marrow and blood is increased but can still function somewhat normally.
- Accelerated Phase: In this phase, the disease progresses more quickly, and the number of abnormal cells increases. The symptoms may become more severe, and the treatment might be less effective.
- Blast Phase: This is the advanced stage of CML, where the number of immature cells increases significantly, and they can invade other organs. The symptoms become more severe, and treatment options become more limited.
Causes of CML:
The exact cause of CML is still unknown. However, researchers have identified genetic mutations, such as the Philadelphia chromosome, as one of the main causes. Exposure to high levels of radiation or certain chemicals might also increase the risk of developing CML.
Symptoms of CML:
The symptoms of CML can vary from person to person, but some common ones include fatigue, weight loss, night sweats, fever, enlarged spleen, and bone pain. However, it’s important to note that some individuals with CML may not experience any symptoms initially.
Diagnosing CML:
To diagnose CML, doctors typically perform a series of tests, including blood tests, bone marrow biopsy, and genetic testing. These tests help identify the presence of the Philadelphia chromosome or the BCR-ABL1 gene and determine the stage of the disease.
Treating CML:
The treatment of CML has evolved significantly in recent years. The goal of treatment is to eliminate as many cancer cells as possible and restore normal blood cell production. The primary treatment for CML is targeted therapy using tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, or nilotinib. In some cases, a bone marrow
